Details
Stereochemistry | RACEMIC |
Molecular Formula | C26H39NO4.C4H4O4 |
Molecular Weight | 545.6643 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC(C)NCC(O)COC1=CC=C(CC(=O)OCCC23CC4CC(CC(C4)C2)C3)C=C1
InChI
InChIKey=WEBILLRFBZTUIX-BTJKTKAUSA-N
InChI=1S/C26H39NO4.C4H4O4/c1-18(2)27-16-23(28)17-31-24-5-3-19(4-6-24)12-25(29)30-8-7-26-13-20-9-21(14-26)11-22(10-20)15-26;5-3(6)1-2-4(7)8/h3-6,18,20-23,27-28H,7-17H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula | C26H39NO4 |
Molecular Weight | 429.5922 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16594634Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/8773927 | https://www.ncbi.nlm.nih.gov/pubmed/10608921
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16594634
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/8773927 | https://www.ncbi.nlm.nih.gov/pubmed/10608921
Adaprolol is a beta-adrenergic antagonist that is being developed as a topical agent to treat glaucoma. Adaprolol demonstrated a safer cardiovascular profile, especially in the population over 70 years old. It was in Phase II clinical trials for the treatment of glaucoma. This research has been discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Cardiac electrophysiologic effects of adaprolol maleate, a new beta-blocker, in closed chest dogs. | 1991 |
|
Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. | 1996 Summer |
|
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. | 2005 Dec 7 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8773927
Rabbit: 0.1 mL of 0.25% solution into each eye
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:38:14 GMT 2023
by
admin
on
Fri Dec 15 16:38:14 GMT 2023
|
Record UNII |
2I8RV6WL9A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2I8RV6WL9A
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL435170
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
121009-31-2
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
C79960
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
BB-85
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
6435805
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY | |||
|
C068416
Created by
admin on Fri Dec 15 16:38:14 GMT 2023 , Edited by admin on Fri Dec 15 16:38:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |